The Moderna<unk> is an mRNA based<unk>  which is approved in the United States to prevent symptomatic<unk> -19 infection. The Moderna<unk>  was the second<unk> to be approved for distribution in the United States, and it was granted Emergency Use Authorization by the United States Food and Drug Administration (FDA) on 18 December 2020.
The approved dosing regimen is two doses, 100 μg each, administered 28 days apart. The<unk>  is approved for individuals 18 years of age and older.
The<unk>  is intended to prevent the<unk> -19 illness, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Moderna<unk>  targets the SARS-CoV-2 spike glycoprotein (S).
COVID-19 Vaccine 
Isolation precautions
HIV post-exposure prophylaxis
United States Antibiogram
Vaccination schedule
HIV testing 
Post exposure prophylaxis antibiotics
Crotalidae polyvalent immune Fab 